Project description:We evaluated blood samples from 6 patients with metastatic melanoma treated with anti-LAG3+anti-PD1 (160+480 mg) in a phase I trial (NCT01968109) using single-cell RNA and T cell receptor (TCR) sequencing (scRNA+TCRαβ-seq, 10X 5') combined with other multiomics profiling (flow, cytokine, TCRb-seq) from a larger cohort of 40 patients. This data set include three time points, including baseline, 1 month, and 3 month. The sorting is CD45+.
Project description:Immune-releated adverse events is a common side effect in immune-checkpoint bloakade therapy like anti-PD1. Here, we performed RNA sequencing of lung tissues after treatment of anti-PD1 or anti-PD1 nanocapsules to evaluate their transcriptomic change related to adverse events. Our analysis has revelaed that nanocapsules which can target tumor tissue more effectively rather than accumulating in healthy tissues cause less transcriptomic change and can potentially prevent immune0related adverse events in lung tissues.
Project description:Differentiating PD-1 + TCF-1 + stem-like CD8 T cells towards a distinct effector T cell population with enhanced anti-tumor and anti-viral efficacy by delivering an engineered IL-2 variant through PD-1 mediated cis-targeting; Single time point at termination (day 3 after 2nd Ab therapy); Tumor model: Panc02-Fluc pancreatic subcutaneous; Groups 0.5 mg/kg muPD-1-IL2v, 10 mg/kg muPD1, 1.5 mg/kg muFAP-IL2v, 10 mg/kg muPD1 + 1.5 mg/kg muFAP-IL2v, Vehicle; scRNA-seq analysis including feature barcoding and TCR-seq.
